

Josep M. Llovet, MD (Barcelona, Spain/ New York, USA)



Brief summary CV

Josep M. Llovet, MD, PhD is **Professor of Research-ICREA** and Head of the Translational lab in Hepatic Oncology at IDIBAPS-Hospital Clínic of Barcelona (Spain), Founder and **Director of the Liver Cancer Program and Full Professor of Medicine** at the Mount Sinai School of Medicine, New York University (USA), and **Director, Master in Translational Medicine** at Faculty of Medicine, University of Barcelona. Professor Llovet obtained his degree in Medicine and Surgery from the University of Barcelona in 1986 and his PhD from the Autonomous University of Barcelona in 1995.

Professor Llovet has been President, Secretary and Founder of the International Liver Cancer Association (ILCA) and Chairman of the European Clinical Practice Guidelines of management of liver cancer (EASL-EORTC). He has published more than 284 articles in peer-reviewed journals such as *New England Journal of Medicine*, *Nature*, *Nature Genetics*, *Lancet*, *Lancet Oncology*, *Cancer Cell*, *Nature Rev Dis Primers*, *Nature Biotech*, *Nature Com*, *Nature Rev Clin Oncol*, *JCO*, *J Clin Invest*, *JNCI* and *Gastroenterology* (**total citations 61709, total impact factor 3620; h index 102**), more than 54 chapters of books, and has delivered more than 600 lectures. He is Senior Editor of *Clinical Cancer Research*. Of note, he has been recognized as a) Top-1% cited researcher in Thomson Reuters, 2014-2018, and b) #1 Most cited investigator in Spain, period 1997-2011.

He has devoted the past 25 years of his career studying the pathogenesis and treatment of liver cancer, and has received the AACR-Landon International Award (2009) for leading the International HCC Genomic Consortium, the International Hans Popper award (2012), Premi Josep Trueta (2013) and was recognized as Fellow of the American Association for the Study of Liver Diseases (FAASLD-2015). He is currently President of the AASLD Special interest group on Hepatobiliary Neoplasia. He has received competitive funding for 75 projects including the European Commission (FP7-HEALTH, HEPROMIC, 2010; Horizon 2020 – HEP-CAR 2016), CRUK-AECC HUNTER - Accelerator Award 2018, DOD 2016 and the US National Institute of Health (R01, 2008; P01-NCI designation 2015), the Spanish National Health Institute, I+D Program and from the Asociación Española Contra el Cancer. He is member of leadership committees in IDIBAPS-Hosp Clínic (Executive Committee) and in Mount Sinai (Executive Management Committee, Tisch Cancer Institute) and Program Committee of ASCO-GI.